Table I.
Patient demographics and history, SARS-CoV-2 vaccine administered, approximate time between dose and hair loss, previously attempted treatments, and treatment prescribed at our institution
| Case | Sex and age | SARS-CoV-2 vaccine administered | Significant medical history | Significant family history | Approximate length of time to flare after vaccine | Severity of hair loss | Previous treatments | Treatment prescribed at our institution |
|---|---|---|---|---|---|---|---|---|
| 1 | Woman, 33 | Moderna | Hepatic steatosis, chronic hepatitis B virus | Brother with AA | 2 months after 2nd dose | Large patches of nonscarring alopecia of the scalp with foci of hair regrowth | ILTAC, pimecrolimus 1% cream, clobetasol 0.05% foam | Tofacitinib citrate 5 mg twice a day |
| 2 | Woman, 57 | Pfizer | Remote history of AA | NA | 4 months after 2nd dose | Widespread nonscarring alopecia of the scalp with foci of hair regrowth | Compounded tofacitinib 2%, clobetasol 0.05% ointment, clobetasol solution | Tofacitinib citrate 5 mg twice a day |
| 3 | Woman, 62 | Moderna | Remote history of AA | NA | 2 months after 2nd dose | Alopecia universalis | NA | Tofacitinib citrate 10 mg twice a day, bimatoprost 0.03% eye drops |
| 4 | Woman, 28 | Pfizer | AA, Hashimoto thyroiditis | NA | Within 1 week after 2nd dose | Alopecia universalis | ILTAC and PRP | Tofacitinib citrate 10 mg twice a day |
| 5 | Woman, 29 | Pfizer | Elevated levels of thyroglobulin antibody and thyroid peroxidase antibody | NA | Within 1 week after 2nd dose | Two patches of nonscarring alopecia of the scalp with areas of regrowth | NA | ILTAC |
| 6 | Man, 22 | Moderna | Elevated thyroid antibody, normal thyroid function tests | NA | 1 month after 2nd dose | Patches of nonscarring alopecia; 30% hair loss from scalp, 80% hair loss from beard | ILTAC | Tofacitinib citrate 10 mg twice a day |
| 7 | Man, 15 | Pfizer | NA | Grandmother with Hashimoto thyroiditis, sister with elevated thyroid antibody | Within 1 week after 2nd dose | Two patches of nonscarring alopecia of the scalp | NA | ILTAC |
| 8 | Man, 61 | Pfizer | Joint pain, on hydroxychloroquine | NA | 2 weeks after 1st dose | Alopecia totalis | NA | Pending possible trial of oral tofacitinib citrate |
| 9 | Man, 16 | Pfizer | NA | NA | Within 1-2 weeks after 1st dose | Patches of nonscarring alopecia with 70% loss of scalp hair; sparse eyebrows and eyelashes | ILTAC | Tofacitinib citrate 10 mg twice a day |
AA, Alopecia areata; ILTAC, intralesional triamcinolone; NA, not applicable; PRP, platelet-rich plasma.